$SPRY

ARS Pharmaceuticals, Inc. (SPRY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001671858 0001671858 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 15, 2026 Date of Report (Date of earliest event report

ARS Pharmaceuticals (NASDAQ:SPRY) said CEO Richard Lowenthal will stop working for the company, effective July 6. Donn Casale, then President, was appointed CEO and Director, taking over July 7. The company also reported payer access updates for neffy, noting no new coverage decisions in the July 1 cycle and continued availability via direct coverage and a retail cash option.

ARS Pharmaceuticals (NASDAQ:SPRY) announced a leadership change. Co-founder and CEO Richard Lowenthal stepped down as employee and officer effective July 6, 2026. Donn Casale, president, was appointed CEO and director effective July 7, 2026. William Blair and analyst Lachlan Hanbury-Brown discussed a more cautious neffy outlook, lowering Q2 neffy revenue to $26.4M and fair value to $21 from $31; SPRY was down 1.6% to $7.97.

ARS Pharmaceuticals (Nasdaq: SPRY) announced CEO succession. Co-founder and CEO Richard Lowenthal will step down as an employee and officer effective July 6, 2026. Donn Casale, currently President, was appointed CEO and director effective July 7, 2026. The company cited Casale’s commercial leadership and experience scaling products, including HEPLISAV-B.

ARS Pharmaceuticals (NASDAQ:SPRY) shares fell 5.4% in after-hours after CEO/co-founder Richard Lowenthal stepped down. President Donn Casale was appointed CEO and director effective July 7, 2026. Lowenthal ceased serving as employee/officer effective July 6. ARS commercializes neffy, an epinephrine nasal spray for Type I allergic reactions/anaphylaxis.

ARS Pharmaceuticals, Inc. (SPRY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001671858 0001671858 2026-07-06 2026-07-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 6, 2026 Date of Report (Date of earliest event reporte

ARS Pharmaceuticals, Inc. (SPRY) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001671858 0001671858 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 24, 2026 Date of Report (Date of earliest event report

Leerink Partners cut its ARS Pharmaceuticals (NASDAQ:SPRY) price target to $24.00 from $25.00 and kept an “outperform” rating, according to Benzinga. The stock traded at $7.90 after falling $2.64. In May 15 results, ARS reported Q1 EPS of -$0.61 (vs -$0.53 expected) on $22.68M revenue (vs $22.20M).

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing beneficial ownership of 4,946,412 shares of ARS Pharmaceuticals, Inc. common stock, which represents 4.98% of the class. The filing indicates BlackRock holds sole voting power for 4,860,113 shares and sole dispositive power for all 4,946,412 shares. This amendment, signed by Spencer Fleming, Managing Director, on April 27, 2026, confirms that BlackRock's ownership is less than 5% and is held for passive investment purposes.

SAN DIEGO, Nov. 26, 2025 ( GLOBE NEWSWIRE ) -- ARS Pharmaceuticals, Inc. ( Nasdaq: SPRY ) , a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced its ...